Skip to content
Zota Healthcare logo

Zota Healthcare

Zota Health Care Ltd

ZOTA NSE
₹1,217.90 −14.30 (−1.16%)
P/E
Not meaningful: loss-making over the last twelve months
View as Markdown
MCP
Close 4 Nov 2026 ₹1,217.90 −310.60 −20.3% 1Y
Start ₹1,528.50

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
−8.47%
Debt to Equity
0.39
EPS (TTM)
−₹30.60
Book Value
₹180.64
Market Cap
—
P/E (TTM)
Not meaningful: loss-making over the last twelve months
P/B
6.74
ROE
−15.00%
Dividend Yield
0.08%
EBITDA
₹26.00 Cr
52W High
₹1,740.00
52W Low
₹1,022.00
Day Range
₹1,207.00 – ₹1,241.90
Volume
33,711

Peer Comparison

Healthcare › Pharmaceuticals

Zota Healthcare peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Zota Healthcare (this company)
₹1,217.90—₹4,239 Cr6.740.08%−15.00%−8.47%₹609 Cr−₹104 Cr
Median 8 companies₹1,587.7038.81₹1,25,337 Cr5.760.44%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

33 Poor

Data confidence 93/100

Category scores

Quality
8
Poor
Returns, margins, earnings quality 22% weight
Valuation
16
Poor
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
36
Poor
Solvency, leverage, coverage 9% weight
Momentum
31
Poor
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is expected to give good quarter

Weaknesses

4
  • Stock is trading at 6.42 times its book value
  • Company has low interest coverage ratio.
  • Company has a low return on equity of -19.9% over last 3 years.
  • Promoter holding has decreased over last 3 years: -16.8%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1243
OscillatorsBullish243
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
44.47
Neutral
MACD (12,26,9)
−4.72
Bearish
SMA (50)
1,226.02
Bearish
SMA (200)
1,251.31
Bearish

As of

Analyst Rating

Based on 1 analysts
BUY100%

1 of 1 analyst rates Buy, 0 Hold, 0 Sell.

As of

BUY
1
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10YIrregular period
5Y+38.39%
3Y+57.01%
1Y+84.25%
TTM+79.12%

Net profit

Net profit growth by window
10YIrregular period
5YTurned to loss
3YLoss widened by ₹68 Cr
1YLoss widened by ₹17 Cr
TTMLoss widened by ₹46 Cr

Operating cash flow

Operating cash flow growth by window
10YIrregular period
5YOutflow widened by ₹81 Cr
3YOutflow widened by ₹80 Cr
1YOutflow widened by ₹32 Cr
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10YIrregular period
5Y+2.59 pp
3Y−1.51 pp
1Y+5.58 pp
TTM+0.78 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2014₹50.00 Cr
Mar 2015₹56.00 Cr
Mar 2019₹85.00 Cr
Mar 2020₹95.00 Cr
Mar 2021₹106 Cr
Mar 2022₹131 Cr
Mar 2023₹139 Cr
Mar 2024₹180 Cr
Mar 2025₹292 Cr
Mar 2026₹538 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2014₹3.00 Cr
Mar 2015₹4.00 Cr
Mar 2019₹6.00 Cr
Mar 2020₹3.00 Cr
Mar 2021₹0.00 Cr
Mar 2022₹9.00 Cr
Mar 2023−₹6.00 Cr
Mar 2024−₹14.00 Cr
Mar 2025−₹57.00 Cr
Mar 2026−₹74.00 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹13.30 Cr +68.4% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Generated 6 Jul 2026
AI opinion · based on fundamentals
Risk high

Zota Health Care Ltd is a small-cap healthcare company with a market cap of ~₹4,970 Cr that has delivered strong revenue growth (85% TTM sales growth) but remains loss-making with a negative PE of -67.6 and a 3-year average ROE of -20%. The stock has appreciated significantly (57% CAGR over 3 years) despite persistent losses, creating a divergence between price momentum and fundamental profitability.

Bull Case 7
  • TTM compounded sales growth of 85% indicates a sharp acceleration in revenue generation
  • 3-year compounded sales CAGR of 57% shows sustained top-line momentum over a meaningful period
  • 5-year compounded sales CAGR of 38% demonstrates a long-term revenue growth trajectory
  • Stock price CAGR of 57% over 3 years reflects strong market confidence and re-rating
  • 5-year stock price CAGR of 45% shows consistent long-term wealth creation for shareholders
  • Company is expected to deliver a good upcoming quarter per available commentary
  • 1-year stock price return of 20% indicates continued positive price momentum
Bear Case 8
  • Negative PE ratio of -67.6 confirms the company is currently loss-making at the net profit level
  • 3-year average ROE of -20% indicates sustained destruction of shareholder equity
  • Last year ROE of -15% shows losses continue even as revenues grow rapidly, suggesting poor unit economics or high cost base
  • TTM compounded profit declined by -22% even as sales grew 85%, indicating severe margin compression or rising losses
  • Price-to-book ratio of 7.22x is elevated for a loss-making company with negative returns on equity
  • Low interest coverage ratio suggests debt servicing is straining cash flows relative to operating earnings
  • Promoter holding decreased by 1.25% in the last quarter, signalling potential insider caution
  • Dividend yield of just 0.07% offers virtually no income cushion for shareholders bearing high equity risk

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

121d ago

TL;DR: Zota Health Care is aggressively scaling its retail pharmacy footprint across multiple brands — DavaIndia (2,825 stores), SKIA, and the new Ugo Generic format — backed by small capital infusions into subsidiaries. No headwinds are visible in recent news, and there are no signs of financial stress with clean promoter shareholding. The trend is clearly expansion-oriented, though the capital-light investments (₹2 Cr each) suggest measured scaling rather than a large capex bet. Execution on multi-brand pharmacy rollout and IT integration will be key to watch in coming quarters.

Positives 4
  • 264 DavaIndia stores in Q1FY27 Jul 1

    Zota opened 264 new DavaIndia pharmacy stores in Q1FY27, expanding total count from 2,579 to 2,825, showing strong retail network momentum.

  • 80% acquisition of Globotask IT Jun 19

    Signed MOU to acquire 80% of Globotask IT Consultancy for ₹25 lakh to secure in-house IT solutions for its growing operations.

  • ₹2 Cr investment in Curexis Jun 22

    Acquired 10 lakh equity shares of Curexis Ventures for ₹2 crore via rights issue to expand SKIA retail pharmacy stores.

Neutral 1
  • FY26 shareholding disclosure filed Jun 15

    Filed FY26 disclosure confirming no new encumbrances on promoter shares. Promoter group comprises 39 individuals and entities.

Quarterly Results

₹ Cr
ZOTA quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
39
45
47
50
56
67
72
97
104
129
143
163
174
199
Expenses
37
41
44
51
58
68
78
95
100
123
143
154
185
196
Operating Profit
1
4
3
−1
−1
−1
−6
2
4
6
0
9
−12
3
OPM %
3.3%
10%
7%
−3%
−2.2%
−1.3%
−8%
2.5%
3.8%
4.9%
−0.3%
5%
−7%
1.5%
Other Income
0
0
0
0
0
1
1
1
1
2
2
−3
2
5
Interest
1
1
1
2
3
3
2
3
3
4
5
5
6
6
Depreciation
3
5
5
7
8
10
11
14
15
19
22
27
28
29
PBT
−3
−1
−3
−10
−12
−13
−18
−14
−13
−14
−26
−26
−44
−27
Tax %
1%
49%
7%
−27%
5%
−4%
2%
−10%
5%
13%
14%
−45%
1%
−4%
Net Profit
−3
−2
−3
−7
−13
−12
−19
−13
−14
−16
−30
−14
−44
−26
EPS (₹)
−1.13
−0.64
−1.14
−2.68
−4.79
−4.41
−6.78
−4.5
−4.81
−5.2
−8.73
−4.09
−12.58
—

Sep 2026: from the results filed on 28 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
ZOTA profit and loss, annual, ₹ crore
Particulars Mar 2011Mar 2012Mar 2014Mar 2015Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
25
38
50
56
85
95
106
131
139
180
292
539
609
Expenses
21
33
43
47
77
90
105
116
132
173
298
520
606
Operating Profit
4
5
6
8
8
5
1
15
7
8
−6
19
3
OPM %
14%
13%
13%
15%
9%
4.8%
0.6%
11%
5%
4.2%
−2%
3.4%
0.5%
Other Income
0
0
0
0
2
2
2
2
2
1
2
1
3
Interest
0
1
1
1
0
0
0
0
3
5
11
17
20
Depreciation
0
1
1
2
1
2
3
4
12
20
43
82
96
PBT
3
3
5
6
8
4
0
12
−5
−16
−58
−80
−110
Tax %
34%
33%
33%
33%
29%
29%
−41%
28%
23%
−11%
−2%
−7%
—
Net Profit
2
2
3
4
6
3
0
9
−6
−14
−57
−74
−104
EPS (₹)
2.17
1.43
1.85
2.12
2.26
1.12
−0.09
3.54
−2.29
−5.55
−19.7
−21.35
−30.6
Div. Payout %
0%
50%
38%
34%
32%
90%
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
42%
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
—

Balance Sheet

₹ Cr
ZOTA balance sheet, annual, ₹ crore
Particulars Mar 2011Mar 2012Mar 2014Mar 2015Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
7
10
12
14
18
25
25
25
25
26
29
35
Reserves
5
3
4
4
51
44
42
64
55
64
195
659
Borrowings
3
6
5
5
0
0
0
15
45
95
140
270
Other Liabilities
5
10
14
17
21
20
19
35
33
43
76
167
Total Liabilities
20
29
35
40
90
88
85
139
158
228
439
1,131
Fixed Assets
8
10
9
8
10
15
14
29
62
103
185
369
CWIP
0
0
0
0
2
0
0
0
3
5
6
15
Investments
0
0
0
0
16
14
10
33
8
5
54
264
Other Assets
12
19
26
32
63
59
61
77
85
116
193
483
Total Assets
20
29
35
40
90
88
85
139
158
228
439
1,131

Cash Flow

₹ Cr
ZOTA cash flow, annual, ₹ crore
Particulars Mar 2011Mar 2012Mar 2014Mar 2015Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
—
—
3
5
−3
6
−1
13
−2
−6
−50
−82
Investing
—
—
−1
−1
9
−4
4
−27
15
−13
−92
−330
Financing
—
—
−2
−4
−6
−3
−2
14
−14
19
145
503
Net Cash Flow
—
—
0
0
−1
−1
1
1
−1
0
3
92
Free Cash Flow
—
—
2
4
−6
−1
−2
10
−13
−23
−96
−208
CFO/OP
—
—
78
81
−12
147
−134
115
2
−59
811
−380

Ratios

ZOTA financial ratios, annual
Particulars Mar 2011Mar 2012Mar 2014Mar 2015Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
75
71
79
77
95
112
99
102
73
55
51
50
Inventory Days
122
141
134
175
208
139
140
121
183
201
277
324
Days Payable
77
90
0
0
104
82
77
78
116
126
111
176
Cash Conversion Cycle
120
123
212
251
199
169
161
145
140
131
217
198
Working Capital Days
102
70
78
80
175
152
143
108
111
75
100
84
ROCE %
—
20%
—
32%
—
6%
−2%
15%
−2%
−7%
−17%
−8%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Zota Healthcare insights

62 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 49.38%
  • Public 28.95%
  • Others 7.45%
  • DIIs 7.30%
  • FIIs 6.92%

0.26% of promoter holding pledged as of Sep 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Zota Healthcare

What does Zota Health Care Ltd do?
Zota Health Care Limited is a renowned pharmaceutical company that manufactures, markets, and exports pharmaceutical, ayurvedic, nutraceutical, and over-the-counter (OTC) products across boundaries into the semi-regulated and regulated markets of Asian Countries markets of African Countries…
Where is Zota Health Care Ltd (ZOTA) listed?
Zota Health Care Ltd trades as ZOTA on the NSE.
Which sector does Zota Health Care Ltd belong to?
Zota Health Care Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Zota Health Care Ltd?
Over the last 52 weeks Zota Health Care Ltd has traded between ₹1,022 and ₹1,740 as of 4 Nov 2026.
Does Zota Health Care Ltd pay dividends?
Zota Health Care Ltd has a dividend yield of 0.08%.
What is the Return on Equity (ROE) of Zota Health Care Ltd?
Zota Health Care Ltd reported a return on equity of -15.00%. Its debt-to-equity ratio is 0.39.

Company Information

Zota Health Care Limited is a renowned pharmaceutical company that manufactures, markets, and exports pharmaceutical, ayurvedic, nutraceutical, and over-the-counter (OTC) products across boundaries into the semi-regulated and regulated markets of Asian Countries markets of African Countries, Russian Countries & Latin America.

Website zotahealthcare.com
Listed 19 Aug 2019
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ZOTA.md for Zota Health Care Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month